Last reviewed · How we verify
Group C: CsAm
CsAm is a calcium channel blocker that inhibits the influx of calcium ions into cardiac and smooth muscle cells.
CsAm is a calcium channel blocker that inhibits the influx of calcium ions into cardiac and smooth muscle cells. Used for Hypertension, Angina pectoris.
At a glance
| Generic name | Group C: CsAm |
|---|---|
| Sponsor | Poitiers University Hospital |
| Drug class | Calcium channel blocker |
| Target | L-type calcium channels |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | Phase 3 |
Mechanism of action
By blocking calcium channels, CsAm reduces the contractility of cardiac muscle and vascular smooth muscle, leading to vasodilation and decreased cardiac workload. This mechanism is thought to contribute to its therapeutic effects in treating hypertension and angina.
Approved indications
- Hypertension
- Angina pectoris
Common side effects
- Dizziness
- Headache
- Nausea
- Edema
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |